GALNS and mucopolysaccharidosis type 4A: Consequently, using the CRISPR/Cas9 system to insert expression cassettes in MPS IVA patient-derived HSPCs could represent a novel alternative used to overcome GVDH while inducing the expression of the functional GALNS enzyme, which can correct bone pathology and systemic manifestations of the disease.